Telix Pharmaceuticals to hold shareholder meeting on ITM Isotope Technologies Munich acquisition
Telix Pharmaceuticals will convene an extraordinary general meeting in November 2026 for shareholders to vote on the proposed acquisition of ITM Isotope Technologies Munich. The deal involves an upfront consideration of USD 1.65 billion, comprising approximately USD 1.25 billion in Telix shares and the assumption of US